Cara Therapeutics Inc (NASDAQ:CARA) reported the appointment of Mani Mohindru, Ph.D., as CFO and Chief Strategy Officer, from August 15, 2017. Derek Chalmers, the CEO and President, reported that they are extremely delighted to welcome Mohindru to the company.
She brings a wealth of financial expertise and strategic development from her extensive leadership in the biopharma market, which they look forward to getting as they develop CR845 via late-stage clinical advancement and towards the marketplace.
Dr. Mohindru reported that they are excited to join Cara’s leadership team at a thrilling time for the firm. CR845 has the prospect to address a broad range of pruritic and pain conditions with unmet medical needs. She looks forward to executing on company’s plans to bring CR845 to people in need while continuing to enhance shareholder value.
Dr. Mohindru brings leadership experience of more than a decade in the biopharma industry to Cara. Most recently, she was a CSO at Curis, Inc., where she played a major role in the management and development of overall corporate plan. She was also accountable for the firm’s involvement with the investment community, establishing extensive associations with industry analysts and shareholders.
Earlier in her career, she had spent many years as an equity research expert covering the biotech sector at ThinkEquity, LLC, UBS and Credit Suisse. She even co-founded Immtox LLC, a biotechnology firm, and was a healthcare industry professional at SAI Healthcare and Axon Healthcare Partners. Dr. Mohindru earned her Ph.D. in neurosciences from renowned Northwestern University.
In the last trading session, the stock price of Cara declined around 0.21% to close the day at $14.33. The drop came at a share volume of 993,825 compared to average share volume of 3.75 million. After the recent decline, the market capitalization of firm stands at $466.89 million.